Edesa Biotech (EDSA) Competitors $2.45 +0.05 (+2.25%) Closing price 03:57 PM EasternExtended Trading$2.45 0.00 (-0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EDSA vs. ANL, GANX, CVM, HOWL, IZTC, ADVM, INKT, UNCY, DRRX, and KALAShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Adlai Nortye (ANL), Gain Therapeutics (GANX), CEL-SCI (CVM), Werewolf Therapeutics (HOWL), Invizyne Technologies (IZTC), Adverum Biotechnologies (ADVM), MiNK Therapeutics (INKT), Unicycive Therapeutics (UNCY), DURECT (DRRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Its Competitors Adlai Nortye Gain Therapeutics CEL-SCI Werewolf Therapeutics Invizyne Technologies Adverum Biotechnologies MiNK Therapeutics Unicycive Therapeutics DURECT KALA BIO Adlai Nortye (NASDAQ:ANL) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Do insiders & institutionals have more ownership in ANL or EDSA? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 22.6% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend ANL or EDSA? Adlai Nortye presently has a consensus target price of $9.00, indicating a potential upside of 437.12%. Edesa Biotech has a consensus target price of $5.00, indicating a potential upside of 103.75%. Given Adlai Nortye's higher probable upside, research analysts plainly believe Adlai Nortye is more favorable than Edesa Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has higher earnings and valuation, ANL or EDSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai NortyeN/AN/A-$51.87MN/AN/AEdesa BiotechN/AN/A-$6.17M-$1.32-1.86 Which has more volatility and risk, ANL or EDSA? Adlai Nortye has a beta of -0.95, indicating that its stock price is 195% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Is ANL or EDSA more profitable? Adlai Nortye's return on equity of 0.00% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Edesa Biotech N/A -162.95%-60.33% Does the media refer more to ANL or EDSA? In the previous week, Adlai Nortye and Adlai Nortye both had 1 articles in the media. Adlai Nortye's average media sentiment score of 1.88 beat Edesa Biotech's score of 1.87 indicating that Adlai Nortye is being referred to more favorably in the media. Company Overall Sentiment Adlai Nortye Very Positive Edesa Biotech Very Positive SummaryAdlai Nortye and Edesa Biotech tied by winning 5 of the 10 factors compared between the two stocks. Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.89M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-1.8621.0831.2626.59Price / SalesN/A364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book3.518.0910.046.68Net Income-$6.17M-$54.08M$3.27B$265.59M7 Day Performance3.11%2.25%3.17%3.42%1 Month Performance5.32%3.41%4.34%1.09%1 Year Performance-44.73%18.61%44.12%23.84% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.2169 of 5 stars$2.45+2.3%$5.00+103.7%-49.0%$16.89MN/A-1.8620Positive NewsGap DownHigh Trading VolumeANLAdlai Nortye1.6568 of 5 stars$1.77+4.8%$9.00+408.2%-43.5%$62.36M$5M0.00127Positive NewsGap DownGANXGain Therapeutics2.1853 of 5 stars$1.77+2.3%$7.80+340.7%+42.0%$62.19M$50K-2.8120News CoverageAnalyst RevisionHigh Trading VolumeCVMCEL-SCI0.6633 of 5 stars$8.92+2.5%N/A-61.2%$61.39MN/A-18.5843News CoverageGap DownHOWLWerewolf Therapeutics3.1659 of 5 stars$1.33flat$8.33+526.6%-41.7%$60.82M$1.88M-0.8140News CoverageAnalyst ForecastIZTCInvizyne TechnologiesN/A$9.70-2.9%N/AN/A$60.64MN/A0.0029ADVMAdverum Biotechnologies4.1255 of 5 stars$2.93+2.4%$19.75+574.1%-58.0%$60.01M$1M-0.37190INKTMiNK Therapeutics2.7441 of 5 stars$14.62-1.9%$37.50+156.5%+95.0%$59.43MN/A-5.0830Gap DownUNCYUnicycive Therapeutics2.6847 of 5 stars$4.08-13.2%$60.00+1,370.6%+19.8%$59.41M$680K-0.999Trending NewsHigh Trading VolumeDRRXDURECT1.8412 of 5 stars$1.90-0.5%N/A+35.0%$59.31M$2.03M-19.0080KALAKALA BIO3.5369 of 5 stars$8.58+3.1%$13.00+51.5%+59.2%$58.42MN/A-1.2630Positive News Related Companies and Tools Related Companies ANL Competitors GANX Competitors CVM Competitors HOWL Competitors IZTC Competitors ADVM Competitors INKT Competitors UNCY Competitors DRRX Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDSA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access